Prot# EDP 305-101: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-alcoholic Steatohepatitis (NASH)

  • Rinella, Mary Eugenia (PD/PI)

Project: Research project

Project Details

Effective start/end date9/11/189/12/21


  • ICON Clinical Research, LLC (EDP 305-101)
  • Enanta Pharmaceuticals, Inc. (EDP 305-101)